• 1. Design, synthesis and effect of the introduction of a propargyloxy group on the fungicidal activities of 1-substituted phenoxypropan-2-amino valinamide carbamate derivatives
  Jian-Qiang Li,Zhi-Peng Wang,Yang Gao,Wei-Guang Zhao RSC Adv. 2016 6 82131
• 2. Design, synthesis, and fungicidal activity of novel carboxylic acid amides represented by N-benzhydryl valinamode carbamates
  Xiu-Jiang Du,Qiang Bian,Hong-Xue Wang,Shu-Jing Yu,Jun-Jie Kou,Zhi-Peng Wang,Zheng-Ming Li,Wei-Guang Zhao Org. Biomol. Chem. 2014 12 5427
• 3. Design, synthesis and antifungal activity of carboxylic acid amide fungicides: part 2: substituted 1-phenyl-2-phenoxyethylamino valinamide carbamates
  Zhi-Peng Wang,Jun-Jie Kou,Yang Gao,Xiu-Jiang Du,Yong-Hong Li,Wei-Guang Zhao RSC Adv. 2015 5 75121
• 4. Potassium formate as a small molecule switch: controlling oxidation–reduction behaviour in a two-step sequence
  Jorgen S. Willemsen,Jan C. M. van Hest,Floris P. J. T. Rutjes Chem. Commun. 2013 49 3143
• 5. The role of amino acid side chains in stabilizing dipeptides: the laser ablation Fourier transform microwave spectrum of Ac-Val-NH2
  I. León,E. R. Alonso,S. Mata,C. Cabezas,M. A. Rodríguez,J.-U. Grabow,J. L. Alonso Phys. Chem. Chem. Phys. 2017 19 24985

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Valinamide (CAS No. 13474-14-1): A Comprehensive Overview

Valinamide, also known by its CAS registry number 13474-14-1, is a compound that has garnered significant attention in the field of biopharmaceuticals due to its potential applications in neurological disorders. This article delves into the properties, pharmacological effects, and recent advancements associated with Valinamide, highlighting its importance as a research subject in contemporary biomedical studies.

Understanding the chemical structure of Valinamide is fundamental to appreciating its biological activity. Chemically, it belongs to the class of compounds known as glutamate receptor agonists, a category that includes substances interacting with glutamatergic systems in the nervous system. This classification positions Valinamide as a promising candidate for exploring therapeutic interventions in conditions characterized by dysregulation of glutamatergic signaling, such as epilepsy and neurodegenerative diseases.

Glutamate receptor agonists are compounds that mimic the action of endogenous neurotransmitters at glutamate receptors. These receptors play a critical role in synaptic plasticity and neuronal communication, making them attractive targets for drug development. Recent studies have highlighted the potential of Valinamide in modulating these pathways, offering new avenues for treating conditions where excessive or insufficient glutamatergic signaling is implicated.

The pharmacokinetics of Valinamide have been extensively studied to determine its bioavailability, half-life, and clearance. These parameters are crucial in drug development as they influence the therapeutic index and dosing regimens. Preclinical investigations have demonstrated that Valinamide exhibits favorable pharmacokinetic properties, supporting its further exploration as a potential pharmaceutical agent.

In terms of therapeutic applications, Valinamide has shown particular promise in the treatment of epilepsy. Epilepsy is characterized by recurrent seizures resulting from abnormal electrical activity in the brain. The modulation of glutamatergic signaling, particularly at NMDA (N-methyl-D-aspartate) receptors, has emerged as a therapeutic strategy for managing this condition. Valinamide’s ability to interact with these receptors makes it a valuable tool in epilepsy research.

Recent advancements in the understanding of Valinamide’s mechanisms of action have been facilitated by advanced imaging techniques and genetic tools. These innovations allow researchers to visualize and manipulate glutamatergic signaling pathways with unprecedented precision, shedding light on the molecular basis of Valinamide’s effects. Such insights are invaluable for optimizing its therapeutic potential and minimizing adverse effects.

Furthermore, Valinamide has been explored in preclinical models of neurodegenerative diseases, such as Alzheimer's disease and Huntington's chorea. These conditions are associated with deficits in synaptic plasticity and glutamatergic dysfunction. By modulating these pathways, Valinamide may offer a novel approach to slowing disease progression and improving cognitive outcomes.

In conclusion, Valinamide (CAS No. 13474-14-1) represents a significant area of research in the biomedical sciences. Its role as a glutamate receptor agonist positions it at the forefront of drug development for neurological disorders. Ongoing studies aim to elucidate its pharmacological profile, optimize its therapeutic potential, and ensure its safe and effective use in clinical settings. As our understanding of glutamatergic signaling continues to evolve, Valinamide is poised to play an increasingly important role in the treatment of neurological diseases.

• 40963-14-2(2-Amino-2,3-dimethylbutyramide)
• 15893-47-7(H-D-Leu-nh2)
• 687-51-4(H-Leu-NH2)
• 906075-26-1(1-Aminocycloheptane-1-carboxamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)